Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04995094
Title Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors HiberCell, Inc.
Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.